A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

Sponsor
Fujian Cancer Hospital
Study ID
NCT06786312
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Small Cell Lung Cancer Extensive Stage

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    250mg, P.O, qd, 21 days per cycle;
  • Adebrelimab — DRUG
    20mg/kg or 1200mg ivgtt, d1, 21 days per cycle;
  • Etoposide Injection — DRUG
    100mg/m\^2 ivgtt for the first, second and third consecutive days, 21 days per cycle.
  • Carboplatin Injection — DRUG
    Day 1 administration, AUC=5, intravenous infusion; One treatment cycle every 21 days.

Study Details

To evaluate the efficacy and safety of apatinib combined with adebrelizumab and EC in the first-line treatment of extensive small cell lung cancer

Key Dates

Start date
Jan 25, 2025
Status verified
Jan 2025
Primary completion
Jul 25, 2027
Completion
Sep 25, 2028

Study Design

Enrollment
34 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental group

Primary Outcome Measure

Progression free survival [ Time Frame: 0ne year ]

Central Contacts

Related Studies